Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Pulmonx CorporationNASDAQ: LUNG
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$12.31M, compared with -$14.56M a year earlier. Trailing-twelve-month EBITDA was -$48.22M.
Context
- EBITDA amounted to 54.3% of revenue in FY2025, down 6.3 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$34.33M (+30.2%) for the fiscal year ending Dec 2026, a step up from the +3.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$12.31M-33.2% QoQ
- Last fiscal yearDec 2025
- -$49.17M+3.2% YoY
- LTMMar 2026
- -$48.22M+9.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.5% | +23.4% | +7.9 pp |
| 1 year | +3.2% | +30.2% | +27.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (49.17M) USD
- Year-over-year change
- +3.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.17M) | +3.2% |
| FY2024 | 2024-12-31 | (50.79M) | +7.8% |
| FY2023 | 2023-12-31 | (55.09M) | +1.6% |
| FY2022 | 2022-12-31 | (55.99M) | -20.1% |
| FY2021 | 2021-12-31 | (46.62M) | — |
EBITDA vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 EBITDA of -$48.22M is the 5th highest of the 10 companies compared; the peer median is -$58.88M.
- Its year-over-year change of +9.4% is the 3rd highest of 10, against a peer median of +0.7%.
- EBITDA amounts to 54.5% of revenue for LUNG, versus a peer median of 41.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$5.79M | -288.4% | -67.3% | 5.7% | |
| LTM Jun 2026 | -$33.12M | +4.6% | — | 41.4% | |
| LTM Mar 2026 | -$33.15M | +15.7% | — | 216.2% | |
| LTM Mar 2026 | -$48.22M | +9.4% | — | 54.5% | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding LUNG) | -$58.88M | +0.7% | -67.3% | 41.4% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.42M | 53.66M | 68.68M | 83.79M | 90.5M |
| Cost of Revenue | 12.79M | 13.8M | 17.92M | 21.79M | 23.36M |
| Gross Profit | 35.63M | 39.87M | 50.75M | 62M | 67.14M |
| Gross Margin | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Research & Development | 13.06M | 15.4M | 18.08M | 17.57M | 19.49M |
| Selling, General & Admin | 69.87M | 83.11M | 94.61M | 102.14M | 101.31M |
| Operating Expenses | 82.93M | 98.5M | 112.69M | 119.71M | 120.8M |
| Depreciation & Amortization | 867K | 1.51M | 1.95M | 1.59M | 1.05M |
| EBITDA | (46.62M) | (55.99M) | (55.09M) | (50.79M) | (49.17M) |
| EBITDA Margin | -96.3% | -104.3% | -80.2% | -60.6% | -54.3% |
| Operating Income | (47.3M) | (58.64M) | (61.94M) | (57.7M) | (53.66M) |
| Operating Margin | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Interest Income | 400K | 1.53M | 5.57M | 5.06M | 2.65M |
| Interest Expense | 829K | 1.07M | 3.23M | 3.51M | 3.16M |
| Other Income / Expenses | (1.01M) | 67K | 1.66M | 1.81M | 286K |
| Income Before Tax | (48.32M) | (58.57M) | (60.27M) | (55.89M) | (53.38M) |
| Pre-Tax Margin | -99.8% | -109.1% | -87.8% | -66.7% | -59.0% |
| Income Tax Expense | 343K | 353K | 571K | 500K | 626K |
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Net Margin | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| EPS (Basic) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| EPS (Diluted) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| Weighted Avg Shares | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
| Weighted Avg Shares (Diluted) | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.